Clinical Trials: Regulatory Audit Findings

Delayed SAE Reporting as a Common Regulatory Audit Finding

Posted on digi By digi

Serious Adverse Events (SAEs) represent life-threatening or medically significant occurrences in participants during a clinical trial. Regulatory frameworks such as ICH E2A, 21 CFR Part 312.32 (FDA), and EU GCP Directive 2005/28/EC mandate sponsors and investigator sites to report SAEs within strict timelines—typically within 24 hours of awareness at the site level and 7–15 days for expedited reporting to regulatory authorities depending on the severity and classification of the event. Any deviation from these timelines directly impacts patient safety, regulatory compliance, and sponsor credibility.
Click to read the full article.

Regulatory Audit Findings, Safety Reporting Audit Findings

Pharmacovigilance Oversight Failures in Clinical Trial Audit Reports

Posted on digi By digi

Pharmacovigilance (PV) is the cornerstone of patient safety in clinical research. It encompasses the detection, assessment, and prevention of adverse effects or any other drug-related issues during the development of investigational products. Regulatory bodies including the FDA, EMA, and MHRA expect sponsors to implement robust pharmacovigilance systems that ensure timely reporting of Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs).
Click to read the full article.

Regulatory Audit Findings, Safety Reporting Audit Findings

Missing SUSAR Documentation Highlighted During Safety Audits

Posted on digi By digi

Suspected Unexpected Serious Adverse Reactions (SUSARs) represent one of the most significant aspects of clinical trial safety oversight. Regulatory agencies such as the FDA, EMA, and MHRA require timely reporting and complete documentation of all SUSARs as part of pharmacovigilance systems. Missing SUSAR documentation during audits signals serious compliance failures and raises concerns about both patient safety and sponsor oversight.
Click to read the full article.

Regulatory Audit Findings, Safety Reporting Audit Findings

What Are the Most Common Regulatory Audit Findings in Clinical Trials?

Posted on digi By digi

Regulatory audits are designed to safeguard both patient safety and data integrity in clinical trials. Inspections carried out by authorities such as the FDA, EMA, MHRA, and WHO assess whether trials adhere to global standards like ICH-GCP. When deficiencies are identified, they are recorded as audit findings, which may range from minor observations to critical violations that threaten trial validity.

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings

How Regulatory Authorities Identify Audit Findings in Clinical Trial Inspections

Posted on digi By digi

Regulatory authorities play a vital role in ensuring that clinical trials adhere to ethical and scientific standards. Inspections conducted by the FDA, EMA, MHRA, and other agencies are not merely routine checks but structured evaluations of compliance with international standards such as ICH-GCP and regional legislations like FDA 21 CFR. Their objective is to identify deficiencies—known as audit findings—that may compromise participant safety or data integrity.

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings

Safety Database Discrepancies Identified in Audit Findings

Posted on digi By digi

Accurate and consistent safety data management is a fundamental requirement in clinical trials. Regulatory authorities such as the FDA, EMA, and MHRA expect sponsors to maintain high-quality pharmacovigilance systems where Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) are consistently captured, reconciled, and reported.

Click to read the full article.

Regulatory Audit Findings, Safety Reporting Audit Findings

Top FDA Audit Findings in Clinical Trials and How to Avoid Them

Posted on digi By digi

The U.S. Food and Drug Administration (FDA) is among the most influential regulatory authorities in the world, and its inspections of clinical trials carry significant weight. Findings from an FDA audit not only impact individual trials but can also influence the credibility of a sponsor’s overall research program. Audit deficiencies may result in Form 483 observations, warning letters, or in severe cases, clinical holds and rejection of a marketing application.

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings

DSUR Submission Delays Reported as Regulatory Observations

Posted on digi By digi

The Development Safety Update Report (DSUR) is a critical pharmacovigilance document required annually for investigational products. It provides regulators with a comprehensive review of the global safety profile of the drug under development, summarizing cumulative safety data, ongoing risk assessments, and important emerging safety signals.

Click to read the full article.

Regulatory Audit Findings, Safety Reporting Audit Findings

EMA Clinical Trial Audit Findings: Lessons for Sponsors and Sites

Posted on digi By digi

The European Medicines Agency (EMA), together with national competent authorities (NCAs), plays a central role in regulating clinical trials across the European Union. Since the implementation of the EU Clinical Trial Regulation (Regulation EU No. 536/2014), regulatory scrutiny has intensified, particularly around transparency, patient safety, and data integrity. Inspections conducted by EMA and NCAs assess whether trials comply with ICH-GCP standards and regional requirements.

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings

Incomplete Serious Adverse Event Follow-up Records in Audit Reports

Posted on digi By digi

Serious Adverse Events (SAEs) are critical safety indicators in clinical trials, requiring timely initial reporting as well as complete follow-up documentation until resolution. Regulatory authorities such as the FDA, EMA, and MHRA emphasize that SAE reporting is not complete until all follow-up data—including laboratory results, diagnostic imaging, and final outcomes—are fully captured and reconciled in the safety database.

Click to read the full article.

Regulatory Audit Findings, Safety Reporting Audit Findings